JusticeItaly Official institution
Italy authorizes Paxfydos, a paclitaxel infusion powder from Sandoz
Italy's medicines agency AIFA has authorized Paxfydos, a paclitaxel powder for infusion, in a decision dated 20 October 2026. Sandoz S.p.A. holds the marketing authorization, and Kymos, S.L. in Spain is responsible for releasing batches. The medicine is hospital-only, and it is not yet assessed for reimbursement.
This summary was generated by AI; the official source prevails.
What does it mean?
Paxfydos is a cancer medicine given by drip into a vein, and it can now be sold in Italy. It is used only in hospitals or similar settings, not at a regular pharmacy.
Who is affected?
Hospitals, cancer patients who receive the infusion, and the companies that sell and supply it.